18:21 , May 25, 2018 |  BC Week In Review  |  Company News

Antengene adds bundle of Karyopharm assets to pipeline

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
22:16 , May 24, 2018 |  BC Extra  |  Company News

Antengene fills pipeline with Karyopharm deal

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
23:14 , Mar 20, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays CRISPR-based screening in human cells could help identify the therapeutic targets of small molecules. The method involved three steps: generating in-frame mutations in human cell lines by engineering them to express CRISPR-associated...
19:10 , Mar 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Colitis Patient sample and mouse studies suggest inhibiting PAK1 and PAK2 could help treat colitis. In samples from patients with inflammatory bowel disease (IBD), levels of a PAK1-induced gene signature were higher in inflamed...
19:51 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample, cell culture and mouse studies suggest inhibiting PAK1 or PAK4 could help treat drug-resistant BRAF-mutant melanoma. In tumor samples from metastatic melanoma patients, high primary tumor levels of PAK1 were associated...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Yes-associated protein 1 (YAP1; YAP); p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1)

Hepatic disease INDICATION: Liver fibrosis Cell culture and mouse studies suggest inhibiting YAP1 or PAK1 could help treat liver fibrosis. In activated rat primary liver myofibroblasts, the YAP1 inhibitor Visudyne verteporfin or a PAK1 inhibitor...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

KPT-9274: Phase I started

Karyopharm began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate oral KPT-9274 with or without extended-release niacin given 3 times a week every other day of a 28-day cycle in about 175 patients....
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

Cancer Research UK, Pangaea Biotech deal

Pangaea and Cancer Research UK’s commercialization and development arm, Cancer Research Technology (CRT), partnered to develop CRT’s p21 protein (Cdc42 Rac)-activated kinase (PAK) inhibitors for cancer. Both partners will be responsible for lead optimization, and...
07:00 , Sep 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Neurofibromatosis p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1) In vitro and mouse studies identified PAK1 inhibitors that could help treat neurofibromatosis type 2 (NF2). PAK1...
07:00 , May 16, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer b-Catenin (CTNNB1); HER2 (EGFR2; ErbB2; neu); p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1) In vitro and mouse studies suggest...